Total Funding
29
35
Total FundingPost-IPO Debt raised
Growth Score
-3 pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
306777
Luminor Medical Technologies develops and commercializes diagnostic tests for diseases lack sensitive and desease-specific tests.
Christopher J. Moreau: President & CEOPast Role: Luminor Medical Technologies, Vice-President of Business Development
James Kinley: CFOPast Role: FGC Health, Chief Financial Officer
About the Company
Luminor Medical Technologies is a medical diagnostic company, focuses on acquiring, developing, and commercializing non-invasive tests for unmet clinical needs in Canada. The company’s products and services include PREVU Skin Cholesterol Test, a non-invasive test that measures cholesterol in the skin tissues to assess risk of coronary artery
disease or heart disease; PSP94, an enzyme linked immunosorbent assay for urine specimens; and testing services. Its diagnostic programs under development comprise cardiovascular disease, preeclampsia, prostate cancer, colorectal cancer, pancreatic cancer, and gastric cancer programs. The company has a partnership agreement with Alere, Inc. for the development of tests for preeclampsia biomarkers.
